<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03815994</url>
  </required_header>
  <id_info>
    <org_study_id>USP 2018-1</org_study_id>
    <nct_id>NCT03815994</nct_id>
  </id_info>
  <brief_title>Neuromuscular Electrical Stimulation in Critically Ill Patients.</brief_title>
  <official_title>Effects of Physical Therapy With Neuromuscular Electrical Stimulation in Critically Ill Patients: a Randomised Crossover Clinical Trial Protocol.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Sao Paulo</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Sao Paulo</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study will investigate the effects of neuromuscular electrical stimulation (NMES) in&#xD;
      critically ill patients. The objective of this study will be investigate the effects of&#xD;
      neuromuscular electrical stimulation (NMES) in critically ill patients.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study will investigate the effects of neuromuscular electrical stimulation (NMES) in&#xD;
      critically ill patients. It will be a randomised crossover clinical trial. Thirty-one&#xD;
      patients will enrolled. Patients will be selected, randomly, to the intervention Protocol&#xD;
      (decubitus position with the limbs raised and NMES) and control (decubitus position with the&#xD;
      limbs raised without NMES).The patients will be allocated in Group 1 (intervention and&#xD;
      control) or group 2 (control and intervention) with a wash-out period of 4 to 6 hours between&#xD;
      them.&#xD;
&#xD;
      The main outcome will be metabolic data. Linear mixed model will be used for analysis of&#xD;
      dependent variables and estimated values of the mean of the differences of each effect.&#xD;
&#xD;
      The results of this study will allow better understanding of the metabolic effects of NMES in&#xD;
      patients critically ill.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Suspended</overall_status>
  <why_stopped>
    This study had to be suspended due to COVID-19 Pandemic.&#xD;
  </why_stopped>
  <start_date type="Actual">November 13, 2018</start_date>
  <completion_date type="Anticipated">January 29, 2021</completion_date>
  <primary_completion_date type="Actual">January 6, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Single (Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change of Oxygen consumption (VO2),from baseline and interventions.</measure>
    <time_frame>VO2 will be taken during the each intervention, it will be taken only the first day</time_frame>
    <description>Change of Oxygen consumption (VO2) will be evaluated by calorimetry</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change of Carbon dioxide production (VCO2) from baseline and interventions.</measure>
    <time_frame>VCO2 will be taken during the each intervention, it will be taken only the first day</time_frame>
    <description>Change of Carbon dioxide production (VCO2) will be evaluated by calorimetry</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Change of Resting energy expenditure (REE) from baseline and interventions.</measure>
    <time_frame>REE will be taken during the each intervention, it will be taken only the first day</time_frame>
    <description>Change of Resting energy expenditure (REE) will be evaluated by calorimetry</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">31</enrollment>
  <condition>Critical Care</condition>
  <condition>Rehabilitation</condition>
  <arm_group>
    <arm_group_label>Experimental: group 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Neuromuscular Electrical Stimulation (NMES) and after decubitus position with the limbs raised without NMES.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>group 2</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>Decubitus Position with the limbs raised withou tNeuromuscular Electrical Stimulation and after Neuromuscular Electrical Stimulation.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Neuromuscular Electrical Stimulation</intervention_name>
    <description>This device produces a muscle contraction in response to a externally generated low-voltage electric impulse, which is conducted through electrodes placed on the skin over the muscle group to be stimulated.</description>
    <arm_group_label>Experimental: group 1</arm_group_label>
    <arm_group_label>group 2</arm_group_label>
    <other_name>Functional Electrical Stimulation</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  All patients that will be admitted to the intensive care unit&#xD;
&#xD;
          -  Hemodynamic stability&#xD;
&#xD;
          -  Mechanical ventilation.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. In general:&#xD;
&#xD;
               -  a. Pregnant women&#xD;
&#xD;
               -  b. Brain death&#xD;
&#xD;
               -  c. Neuromuscular diseases&#xD;
&#xD;
               -  d. Use of pre-existing neuromuscular blocker in the last 24 hours, prior to the&#xD;
                  study protocol.&#xD;
&#xD;
          2. Contraindications for the use of NMES:&#xD;
&#xD;
               -  a. Fractures&#xD;
&#xD;
               -  b. Burns&#xD;
&#xD;
               -  c. Skin lesions&#xD;
&#xD;
               -  d. Systemic vascular impairment diseases such as systemic lupus erythematosus,&#xD;
                  thromboembolic disease, deep vein thrombosis (which was not therapeutically&#xD;
                  anticoagulated for a time greater than 36 hours)&#xD;
&#xD;
               -  e. Lower limb amputations&#xD;
&#xD;
               -  f. Cardiac pacemaker,&#xD;
&#xD;
               -  g. Thrombocytopenia less than 20,000/mm3&#xD;
&#xD;
               -  h. BMI greater than 35 kg/m2&#xD;
&#xD;
               -  i. Important lower extremity oedema&#xD;
&#xD;
               -  j. Agitation and/or signs of pain during the electrical stimulation.&#xD;
&#xD;
          3. Contraindications to begin or continue NMES procedure:&#xD;
&#xD;
               -  a. Mean arterial blood pressure less than 65 mmHg&#xD;
&#xD;
               -  b. Use of vasopressor &gt;50% of themaximum dose (dopamine &gt;12.5 μg/kg per minute;&#xD;
                  vasopressin &gt;0.02U/min and norepinephrine &gt;1 μg/kg per minute),&#xD;
&#xD;
               -  c. Heart rate &lt;50 or &gt;140bpm&#xD;
&#xD;
               -  d. Arrhythmias with hemodynamic consequences&#xD;
&#xD;
               -  e. Myocardial ischemia,&#xD;
&#xD;
               -  f. Temperature &lt;34 or &gt;39oC&#xD;
&#xD;
               -  g. Intracranial pressure &gt;20 cmH2O&#xD;
&#xD;
               -  h. Decrease in 10% of SpO2 baseline value or &lt;88% for more than one minute.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ada C Gastaldi, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ribeirao Preto Medicine School-University of São Paulo</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Clinics Hospital</name>
      <address>
        <city>Ribeirão Preto</city>
        <state>São Paulo</state>
        <zip>14049-900</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>November 13, 2018</study_first_submitted>
  <study_first_submitted_qc>January 18, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">January 25, 2019</study_first_posted>
  <last_update_submitted>February 2, 2021</last_update_submitted>
  <last_update_submitted_qc>February 2, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Sao Paulo</investigator_affiliation>
    <investigator_full_name>Ada Clarice Gastaldi</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Physical therapy modalities,</keyword>
  <keyword>Electric stimulation therapy</keyword>
  <keyword>Indirect calorimetry</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Critical Illness</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>All of the individual participant data collected during the trial, after deidentification, will be available.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>The data will be available immediately following publication and for five years.</ipd_time_frame>
    <ipd_access_criteria>The data will be available from the principal investigator upon reasonable request.</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

